ARTICLE | Clinical News
IPI-940: Phase I data
November 8, 2010 8:00 AM UTC
A Phase I trial in 48 healthy volunteers showed that single ascending-doses of oral IPI-940 were well tolerated with no dose-limiting toxicities or significant changes in clinical laboratory values, v...